Current polygenic scores offer only modest clinical benefits for guiding drug choice in dyslipidemia and hypertension.
Variance-stabilizing transformation corrects spurious pharmacogenetic associations introduced by biomarker scaling. Genetic variation informs drug choice for dyslipidemia and hypertension, but current polygenic scores provide only modest benefits in clinical application.
Takeuchi et al. (Fri,) studied this question.